Latest publications
Oncolytic Virus Immunotherapy.
- Laboratory of Oncolytic-Virus-Immuno-Therapeutics
2021 Jul. Cancers.13(15):3672.
Virotherapy in Germany-Recent activities in virus engineering, preclinical development, and clinical studies.
- Laboratory of Oncolytic-Virus-Immuno-Therapeutics
2021 Jul. Viruses.13(8):1420.
Oncolytic H-1 parvovirus binds to sialic acid on laminins for cell attachment and entry.
- Laboratory of Oncolytic-Virus-Immuno-Therapeutics
- NORLUX Neuro-Oncology Laboratory
2021 Jun. Nat Commun.12(1):3834.
Parvovirus-based combinatorial immunotherapy: A reinforced therapeutic strategy against poor-prognosis solid cancers.
- Laboratory of Oncolytic-Virus-Immuno-Therapeutics
2021 Jan. Cancers.13(2).
Oncolytic H-1 parvovirus enters cancer cells through clathrin-mediated endocytosis.
- Laboratory of Oncolytic-Virus-Immuno-Therapeutics
2020 Oct. Viruses.12(10).
A roadmap for the success of oncolytic parvovirus-based anticancer therapies.
- Laboratory of Oncolytic-Virus-Immuno-Therapeutics
2020 Sep. Annu Rev Virol.7(1):537-557. Epub 2020 Jun 29.
Suicide gene therapy for the treatment of high-grade glioma: past lessons, present trends, and future prospects.
- NORLUX Neuro-Oncology Laboratory
- Laboratory of Oncolytic-Virus-Immuno-Therapeutics
2020 Feb. Neurooncol Adv.2(1):vdaa013.
Immune conversion of tumor microenvironment by oncolytic viruses: the protoparvovirus H-1PV case study.
- Laboratory of Oncolytic-Virus-Immuno-Therapeutics
2019 Aug. Front Immunol.10:1848.
H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future.
- Laboratory of Oncolytic-Virus-Immuno-Therapeutics
2019 Jun. Viruses.11(6).
Cholestasis induced liver pathology results in dysfunctional immune responses after arenavirus infection.
- Laboratory of Oncolytic-Virus-Immuno-Therapeutics
2018 Sep. Sci Rep.8(1):12179.
Inhibition of HIF1alpha-dependent upregulation of Phospho-l-Plastin resensitizes multiple myeloma cells to frontline therapy.
- Tumor Immunotherapy and Microenvironment
- Computational Biomedicine
- Laboratory of Oncolytic-Virus-Immuno-Therapeutics
2018 May. Int J Mol Sci.19(6):1551.
Virotherapy Research in Germany: From Engineering to Translation.
- Laboratory of Oncolytic-Virus-Immuno-Therapeutics
2017 Oct. Hum Gene Ther.28(10):800-819.
A Track Record on SHOX: From Basic Research to Complex Models and Therapy.
- Laboratory of Oncolytic-Virus-Immuno-Therapeutics
2016 Sep. Endocr Rev.37(4):417-48. Epub 2016 Jun 29.
A high rate of telomeric sister chromatid exchange occurs in chronic lymphocytic leukaemia B-cells.
- Tumor Stroma Interactions
- Integrated BioBank of Luxembourg
- Laboratory of Oncolytic-Virus-Immuno-Therapeutics
2016 Jul. Br J Haematol.174(1):57-70. Epub 2016 Mar 11.
Epigenetic activity of peroxisome proliferator-activated receptor gamma agonists increases the anticancer effect of histone deacetylase inhibitors on multiple myeloma cells.
- Tumor Immunotherapy and Microenvironment
- Translational Radiomics
- Laboratory of Oncolytic-Virus-Immuno-Therapeutics
2015 Jun. PLoS One.10(6):e0130339.
Oncolytic parvoviruses: from basic virology to clinical applications.
- Laboratory of Oncolytic-Virus-Immuno-Therapeutics
2015 Jan. Virol J.12:6.
Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas.
- Laboratory of Oncolytic-Virus-Immuno-Therapeutics
2013 Oct. EMBO Mol Med.5(10):1537-55. Epub 2013 Sep 17.
Generation of an adenovirus-parvovirus chimera with enhanced oncolytic potential.
- Laboratory of Oncolytic-Virus-Immuno-Therapeutics
2012 Oct. J Virol.86(19):10418-31. Epub 2012 Jul 11.
Molecular pathways: rodent parvoviruses--mechanisms of oncolysis and prospects for clinical cancer treatment.
- Laboratory of Oncolytic-Virus-Immuno-Therapeutics
2012 Jul. Clin Cancer Res.18(13):3516-23. Epub 2012 May 7.
Through its nonstructural protein NS1, parvovirus H-1 induces apoptosis via accumulation of reactive oxygen species.
- Laboratory of Oncolytic-Virus-Immuno-Therapeutics
2010 Jun. J Virol.84(12):5909-22. Epub 2010 Apr 7.